Literature DB >> 17349862

Cholinergic circuits and signaling in the pathophysiology of schizophrenia.

Joshua A Berman1, David A Talmage, Lorna W Role.   

Abstract

Central cholinergic signaling has long been associated with aspects of memory, motivation, and mood, each affected functions in neuropsychiatric disorders such as schizophrenia. In this chapter, we review evidence related to the core hypothesis that dysregulation of central cholinergic signaling contributes to the pathophysiology of schizophrenia. Although central cholinergic circuits are resistant to simplification-particularly when one tries to parse the contributions of various classes of cholinergic receptors to disease related phenomena--the potential role of ACh signaling in Schizophrenia pathophysiology deserves careful consideration for prospective therapeutics. The established role of cholinergic circuits in attentional tuning is considered along with recent work on how the patterning of cholinergic activity may modulate corticostriatal circuits affected in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17349862      PMCID: PMC2377023          DOI: 10.1016/S0074-7742(06)78007-2

Source DB:  PubMed          Journal:  Int Rev Neurobiol        ISSN: 0074-7742            Impact factor:   3.230


  157 in total

1.  Prenatal determinants of schizophrenia: what we have learned thus far?

Authors:  Michaeline Bresnahan; Catherine A Schaefer; Alan S Brown; Ezra S Susser
Journal:  Epidemiol Psichiatr Soc       Date:  2005 Oct-Dec

2.  Cholinergic basal forebrain neurons burst with theta during waking and paradoxical sleep.

Authors:  Maan Gee Lee; Oum K Hassani; Angel Alonso; Barbara E Jones
Journal:  J Neurosci       Date:  2005-04-27       Impact factor: 6.167

3.  Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons.

Authors:  Zhongfeng Wang; Li Kai; Michelle Day; Jennifer Ronesi; Henry H Yin; Jun Ding; Tatiana Tkatch; David M Lovinger; D James Surmeier
Journal:  Neuron       Date:  2006-05-04       Impact factor: 17.173

4.  Muscarinic1 and 2 receptor mRNA in the human caudate-putamen: no change in m1 mRNA in schizophrenia.

Authors:  B Dean; J M Crook; G Pavey; K Opeskin; D L Copolov
Journal:  Mol Psychiatry       Date:  2000-03       Impact factor: 15.992

5.  Early specification of striatal projection neurons and interneuronal subtypes in the lateral and medial ganglionic eminence.

Authors:  M Olsson; A Björklund; K Campbell
Journal:  Neuroscience       Date:  1998-06       Impact factor: 3.590

6.  Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia.

Authors:  Sherry Leonard; Judith Gault; Jan Hopkins; Judith Logel; Ruby Vianzon; Margaret Short; Carla Drebing; Ralph Berger; Diana Venn; Pinkhas Sirota; Gary Zerbe; Ann Olincy; Randal G Ross; Lawrence E Adler; Robert Freedman
Journal:  Arch Gen Psychiatry       Date:  2002-12

7.  Effects of perinatal buprenorphine and methadone exposures on striatal cholinergic ontogeny.

Authors:  Susan E Robinson
Journal:  Neurotoxicol Teratol       Date:  2002 Mar-Apr       Impact factor: 3.763

Review 8.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.

Authors:  P J Harrison; D R Weinberger
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

9.  Augmenting atypical antipsychotics with a cognitive enhancer (donepezil) improves regional brain activity in schizophrenia patients: a pilot double-blind placebo controlled BOLD fMRI study.

Authors:  Ziad Nahas; Mark S George; Michael D Horner; John S Markowitz; Xingbao Li; Jeffrey P Lorberbaum; Susan D Owens; Susan McGurk; Lindsay DeVane; S Craig Risch
Journal:  Neurocase       Date:  2003-06       Impact factor: 0.881

10.  A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia.

Authors:  Onder Tuğal; Kâzm M Yazici; A Elif Anil Yağcioğlu; Ahmet Göğüş
Journal:  Int J Neuropsychopharmacol       Date:  2004-01-23       Impact factor: 5.176

View more
  18 in total

1.  Direct excitation of parvalbumin-positive interneurons by M1 muscarinic acetylcholine receptors: roles in cellular excitability, inhibitory transmission and cognition.

Authors:  Feng Yi; Jackson Ball; Kurt E Stoll; Vaishali C Satpute; Samantha M Mitchell; Jordan L Pauli; Benjamin B Holloway; April D Johnston; Neil M Nathanson; Karl Deisseroth; David J Gerber; Susumu Tonegawa; J Josh Lawrence
Journal:  J Physiol       Date:  2014-05-30       Impact factor: 5.182

2.  Activation of alpha7 nicotinic and NMDA receptors is necessary for performance in a working memory task.

Authors:  David Phenis; Sarah A Vunck; Valentina Valentini; Hugo Arias; Robert Schwarcz; John P Bruno
Journal:  Psychopharmacology (Berl)       Date:  2020-03-11       Impact factor: 4.530

Review 3.  Allosteric Modulation of GPCRs: New Insights and Potential Utility for Treatment of Schizophrenia and Other CNS Disorders.

Authors:  Daniel J Foster; P Jeffrey Conn
Journal:  Neuron       Date:  2017-05-03       Impact factor: 17.173

Review 4.  Signaling pathways in schizophrenia: emerging targets and therapeutic strategies.

Authors:  Caline S Karam; Jacob S Ballon; Nancy M Bivens; Zachary Freyberg; Ragy R Girgis; José E Lizardi-Ortiz; Sander Markx; Jeffrey A Lieberman; Jonathan A Javitch
Journal:  Trends Pharmacol Sci       Date:  2010-06-25       Impact factor: 14.819

5.  Potentiation of M1 Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model.

Authors:  A Ghoshal; J M Rook; J W Dickerson; G N Roop; R D Morrison; N Jalan-Sakrikar; A Lamsal; M J Noetzel; M S Poslusney; M R Wood; B J Melancon; S R Stauffer; Z Xiang; J S Daniels; C M Niswender; C K Jones; C W Lindsley; P J Conn
Journal:  Neuropsychopharmacology       Date:  2015-06-25       Impact factor: 7.853

6.  M3 muscarinic acetylcholine receptor expression confers differential cholinergic modulation to neurochemically distinct hippocampal basket cell subtypes.

Authors:  Christian A Cea-del Rio; J Josh Lawrence; Ludovic Tricoire; Ferenc Erdelyi; Gabor Szabo; Chris J McBain
Journal:  J Neurosci       Date:  2010-04-28       Impact factor: 6.167

7.  The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese patients with bipolar disorder and schizophrenia.

Authors:  Shiou-Lan Chen; Sheng-Yu Lee; Yun-Hsuan Chang; Shih-Heng Chen; Chun-Hsien Chu; Tzu-Yun Wang; Po-See Chen; I-Hui Lee; Yen-Kuang Yang; Jau-Shyong Hong; Ru-Band Lu
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-01-25       Impact factor: 5.067

8.  Prefrontal gray matter morphology mediates the association between serum anticholinergicity and cognitive functioning in early course schizophrenia.

Authors:  Jessica A Wojtalik; Shaun M Eack; Bruce G Pollock; Matcheri S Keshavan
Journal:  Psychiatry Res       Date:  2012-11-15       Impact factor: 3.222

9.  Inhibition of acetylcholinesterase activity in brain and behavioral analysis in adult rats after chronic administration of fenproporex.

Authors:  Gislaine T Rezin; Giselli Scaini; Gabriela K Ferreira; Mariane R Cardoso; Cinara L Gonçalves; Larissa S Constantino; Pedro F Deroza; Fernando V Ghedim; Samira S Valvassori; Wilson R Resende; João Quevedo; Alexandra I Zugno; Emilio L Streck
Journal:  Metab Brain Dis       Date:  2012-07-27       Impact factor: 3.584

10.  Synthesis and in vitro and in vivo evaluation of 18F-labeled positron emission tomography (PET) ligands for imaging the vesicular acetylcholine transporter.

Authors:  Zhude Tu; Simon M N Efange; Jinbin Xu; Shihong Li; Lynne A Jones; Stanley M Parsons; Robert H Mach
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.